0NWK.LSE Valerio Therapeutics
- Market cap
- EUR 8.98M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2021.
Is 0NWK.LSE undervalued?
Graham numberThe Graham number of Valerio Therapeutics cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Valerio Therapeutics fundamental analysis
No fundamental analysis for Valerio Therapeutics yet.
Valerio Therapeutics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Valerio Therapeutics
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody" drug conjug…
Full company profileValerio Therapeutics financial statements
2021 annualized: Fiscal year 2021 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2021, the balance sheet is the latest quarter. Figures change when the annual report is published.
Valerio Therapeutics annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 Anlz |
|---|---|---|---|---|---|
| Cash Flow | |||||
| Operating Cash Flow | -28.3M | -11.3M | -7.70M | -4.68M | -6.58M |
| Capital Expenditure | 65.0K | 45.0K | 26.0K | 119K | 16.0K |
What these items mean
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
Valerio Therapeutics dividends
Valerio Therapeutics has not paid dividends in the last 4 fiscal years.
Last stock split: 766:761 on Mar 17, 2021.
Who owns Valerio Therapeutics
- Insiders 29.94%
- Institutions 37.45%
- Public & others 32.61%
- Shares outstanding 50.6M
- Free float 147M
Valerio Therapeutics company profile
- Company name
- Valerio Therapeutics
- Ticker
- 0NWK.LSE
- ISIN
- FR0010095596
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 41
- Fiscal year end
- December
- Address
- 49, boulevard du GEnEral Martial Valin, Paris, France, 75015
- Phone
- 33 1 45 58 76 00
- Website
- valeriotx.com
About Valerio Therapeutics
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody" drug conjugates, and chimeric antigen receptors. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
Valerio Therapeutics management
2- Dr. Gilles Besin Ph.D.CEO & Director
- Mr. Wael Jdey Ph.D.CTO & Director